Home › Compare › PRCF vs JNJ

PRCF vs JNJ: Dividend Comparison 2026

PRCF yields 20000000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRCF wins by $4.875981653489057e+49M in total portfolio value
10 years
PRCF
PRCF
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full PRCF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — PRCF vs JNJ

📍 PRCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRCFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRCF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PRCF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRCF
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, PRCF beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRCF + JNJ for your $10,000?

PRCF: 50%JNJ: 50%
100% JNJ50/50100% PRCF
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PRCF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRCF buys
0
JNJ buys
0
No recent congressional trades found for PRCF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRCFJNJ
Forward yield20000000.00% ✓2.14%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$4.875981653489057e+49M$30.5K ✓
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$4,749.88
Total dividends collected$4.875978515990276e+49M$15.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PRCF vs JNJ ($10,000, DRIP)

YearPRCF PortfolioPRCF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$10,594$274.49+$2000.00M → PRCF
2$373,835,915,712,384$373,833,775,700,934.50$11,294$360.69+$373835915.70M → PRCF
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$12,133$476.91+$65304953364964.96M → PRCF
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$13,156$635.42+$10661728832755499008.00M → PRCF
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$14,432$854.61+$1.626767783781495e+24M → PRCF
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$16,056$1,162.76+$2.319743300546251e+29M → PRCF
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$18,175$1,604.53+$3.0915106403922057e+34M → PRCF
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$21,009$2,252.68+$3.8505079858392777e+39M → PRCF
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$24,911$3,229.73+$4.4821026103531426e+44M → PRCF
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$4.875981653489057e+49M → PRCF

PRCF vs JNJ: Complete Analysis 2026

PRCF — Stock

Protein Reactor Combined Fuels Inc manufactures and sells coffee products; and wholesale/retail of coffee beans, as well as offers coffee shop franchises under the Preacher's Coffee brand name. The company provides coffee in various forms, such as Green beans, Roasted, and Ground. It also involves in growing, harvesting, and processing Arabica type of coffee beans. The company sells its products through wholesale and retail to coffee traders, as well as to coffee shops worldwide via direct distribution and through international freight forwarders. The company was formerly known as Preachers Coffee, Inc. and changed its name to Protein Reactor Combined Fuels Inc in February 2011. Protein Reactor Combined Fuels Inc was founded in 2003 and is based in Tampa, Florida.

Full PRCF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this PRCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRCF vs SCHDPRCF vs JEPIPRCF vs OPRCF vs KOPRCF vs MAINPRCF vs ABBVPRCF vs MRKPRCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.